search
Back to results

Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D

Primary Purpose

Type 2-diabetes

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
100% O2 in oxygen chamber
21% O2 in oxygen chamber
Sponsored by
German Diabetes Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2-diabetes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 and ≤ 75 years
  • Type 2 diabetes
  • HbA1c ≥ 6 and ≤ 9%
  • BMI ≤ 35 kg / m2

Exclusion Criteria:

  • Treatment with thiazolidinedione in the last 6 months
  • Uncontrolled hyperglycemia (FPG ≥ 240 mg / dl)
  • vitamin supplement (washing out at least 4 weeks)
  • Patients requiring revascularization
  • Serum CRP ≥ 5 mg / dl
  • Previous treatment for HBO therapy
  • Secondary diabets according to ADA criteria (type 3 B-H, eg pancreopriver diabetes)
  • Type 4 diabetes (gestational diabetes), pregnancy
  • poor glycemic control (HbA1c> 9.0%)
  • Hyperlipidemia (low density triglycerides and lipoproteins ≥ double upper Reference limit)

Sites / Locations

  • German Diabetes Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Hyperbaric oxygenation

Ambient Air

Arm Description

Patients with T2D receive an 2 hour treatment with 100 % oxygen in a hyperbaric chamber

Patients with T2D receive an 2 hour treatment with 21% oxygen in a hyperbaric chamber

Outcomes

Primary Outcome Measures

Change in rate of glucose disappearance
measurement of whole body insulin sensitivity with hyperinsulinamic euglycemic clamp test

Secondary Outcome Measures

Full Information

First Posted
September 11, 2019
Last Updated
August 11, 2023
Sponsor
German Diabetes Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04219215
Brief Title
Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D
Official Title
Acute Hyperbaric Oxygen (HBO) Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
February 1, 2020 (Actual)
Primary Completion Date
September 20, 2022 (Actual)
Study Completion Date
September 20, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
German Diabetes Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Diabetes mellitus type 2 (T2D) is characterized by insulin resistance of liver and skeletal muscle, which is at least partly due to impaired muscle mitochondrial function. Long-term HBO therapy, as applied for treating the diabetic foot syndrome, has been shown to improve blood glucose concentrations. To study the underlying mechanisms, we want to examin the short-term effect of HBO treatment on insulin sensitivity and mitochondrial oxidative capacity and production of reactive oxygen species (ROS) in a randomized, double blinded, placebo-controlled cross-over trial.
Detailed Description
In total 14 patients are planned. Each participant participates in both experimental parts (100% O2 and ambient air). They are examined immediately after each HBO/ ambient air therapy. The allocation is randomized treated every three weeks with 2-hour therapies using pure O2 or indoor air. Randomized and double-blinded in a cross-over setting, one group of patients with type 2 diabetes is first treated with HBO therapy and the other group is first treated with room air. Here, an ambient pressure of 2.4 ATM is built up and then administered for respiration over a total of 90 minutes of pure O2. Patients are examined on two consecutive days for each part of the study.On the first day serum samples are taken and a sample is taken from the vastus lateralis muscle. A magnetic resonance spectroscopic examination (MRS) is performed on the patient subsequently. In this case, phosphorus metabolites (absolute quantification of ATP, Pi) and the ATP synthase flow rate (fATP) are determined non-invasively by means of 31P MRS and TG storage (HCL) by means of 1H-MRS. On the next day of the trial patients are treated with HBO therapy or room air. A hyperinsulinemic-euglycemic clamp test (120-300 min) with administration of deuterated glucose (D- [6,6-2H2] glucose) (0-120 min) to measure muscular and hepatic insulin resistance will be performed after the end of HBO therapy or room air treatment performed. Indirect calorimetry determines energy consumption and substrate selection (lipid and glucose oxidation) in hyperinsulinaemia. After the end of the HBO therapy or room air treatment and 30 minutes after the start of the clamp test, a sample is taken from the vastus lateralis muscle again.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2-diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hyperbaric oxygenation
Arm Type
Experimental
Arm Description
Patients with T2D receive an 2 hour treatment with 100 % oxygen in a hyperbaric chamber
Arm Title
Ambient Air
Arm Type
Experimental
Arm Description
Patients with T2D receive an 2 hour treatment with 21% oxygen in a hyperbaric chamber
Intervention Type
Device
Intervention Name(s)
100% O2 in oxygen chamber
Intervention Description
Application of 100% O2 in an hyperbaric oxygen chamber
Intervention Type
Device
Intervention Name(s)
21% O2 in oxygen chamber
Intervention Description
Application of ambient air (21% O2) in an hyperbaric oxygen chamber
Primary Outcome Measure Information:
Title
Change in rate of glucose disappearance
Description
measurement of whole body insulin sensitivity with hyperinsulinamic euglycemic clamp test
Time Frame
12 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 and ≤ 75 years Type 2 diabetes HbA1c ≥ 6 and ≤ 9% BMI ≤ 35 kg / m2 Exclusion Criteria: Treatment with thiazolidinedione in the last 6 months Uncontrolled hyperglycemia (FPG ≥ 240 mg / dl) vitamin supplement (washing out at least 4 weeks) Patients requiring revascularization Serum CRP ≥ 5 mg / dl Previous treatment for HBO therapy Secondary diabets according to ADA criteria (type 3 B-H, eg pancreopriver diabetes) Type 4 diabetes (gestational diabetes), pregnancy poor glycemic control (HbA1c> 9.0%) Hyperlipidemia (low density triglycerides and lipoproteins ≥ double upper Reference limit)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Roden, Prof., MD
Organizational Affiliation
German Diabetes Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
German Diabetes Center
City
Düsseldorf
State/Province
NRW
ZIP/Postal Code
40225
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36178534
Citation
Sarabhai T, Mastrototaro L, Kahl S, Bonhof GJ, Jonuscheit M, Bobrov P, Katsuyama H, Guthoff R, Wolkersdorfer M, Herder C, Meuth SG, Dreyer S, Roden M. Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial. Diabetologia. 2023 Jan;66(1):57-69. doi: 10.1007/s00125-022-05797-0. Epub 2022 Sep 30.
Results Reference
derived

Learn more about this trial

Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D

We'll reach out to this number within 24 hrs